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Heterozygous inactivating mutations in the Gs gene cause
Albright’s hereditary osteodystrophy. Consistent with the ob-
servation that only maternally inherited mutations lead to
resistance to hormone action [pseudohypoparathyroidism
type Ia (PHP Ia)], recent studies provided evidence for a pre-
dominant maternal origin of Gs transcripts in endocrine or-
gans, such as thyroid, gonad, and pituitary. The aim of this
study was to investigate the presence of pituitary resistance
to hypothalamic hormones acting via Gs-coupled receptors
in patients with PHP Ia. Six of nine patients showed an im-
paired GH responsiveness to GHRH plus arginine, consistent
with a complete GH deficiency (GH peak from 2.6–8.6g/liter,
normal > 16.5), and partial (GH peak 13.9 and 13.6g/liter) and
normal responses were found in two and one patient, respec-
tively. Accordingly, IGF-I levels were below and in the low-
normal range in seven and two patients. All patients had a
normal cortisol response to 1 g ACTH test, suggesting a nor-
mal corticotroph function that was confirmed by a normal
ACTH and cortisol response to CRH test in three patients. In
conclusion, we report that in addition to PTH and TSH resis-
tance, patients with PHP Ia display variable degrees of GHRH
resistance, consistent with Gs imprinting in human
pituitary. (J Clin Endocrinol Metab 88: 4070–4074, 2003)
PSEUDOHYPOPARATHYROIDISM (PHP) REFERS to aheterogeneous group of rare metabolic disorders char-
acterized by hypocalcemia and hyperphosphatemia caused
by PTH resistance (1, 2). Heterozygous loss of function mu-
tations in stimulatory guanine nucleotide binding protein
-subunit gene inherited from the mother leads to PHP type
Ia (PHP Ia). PHP Ia is a disease in which Albright’s hereditary
osteodystrophy (AHO), a disorder characterized by a con-
stellation of physical features (short stature, obesity, round
face, brachydactyly, and sc calcifications), is associated with
end organ resistance to the action of different hormones that
activate Gs-coupled receptors, primarily PTH, TSH, and go-
nadotropins (reviewed in Refs. 3–5 and the Web site: http://
mammary.nih.gov/aho/). Interestingly, when the same mu-
tations are inherited from the father, patients show the
physical abnormalities of AHO, without evidence of hor-
mone resistance (pseudo-pseudohypoparathyroidism) (6, 7).
This pattern of inheritance is consistent with a tissue-specific
Gs paternal allele imprinting, an epigenetic phenomenon
by which the paternal allele undergoes partial or total loss of
expression (8, 9). The human Gs gene GNAS maps on chro-
mosome 20q13, and there is increasing evidence that this
locus is under complex imprinting control with multiple
maternally, paternally, and biallelically alternatively spliced
transcripts encoding multiple products in humans and an-
imals (10–14). Considering the PHP Ia phenotype, Gs gene
imprinting is predicted to be limited mainly to tissues, such
as the renal proximal tubule, thyroid, and gonad, in which
there is a parent-of-origin-specific difference in hormone re-
sponsiveness (15–17). Indeed, although previous expression
studies failed to demonstrate monoallelic Gs expression in
various human fetal tissues (18, 19), recent reports demon-
strated that in the thyroid, gonad, and pituitary Gs tran-
scription mainly derives from the maternal allele (20–22).
Because the pituitary is not classically included among the
target organs resistant to hormone action in PHP Ia, the aim
of the study was to evaluate the presence of pituitary defects
involving pituitary hormones, primarily GH and ACTH that
are regulated by neuropeptides acting through Gs-coupled
receptors, in patients with PHP Ia.
Patients and Methods
Patients
The study included nine patients affected with PHP Ia, six of whom
have already been described in a previous report by our group (23). Four
of these patients are related to each other: in particular, patients I and
II are mother and daughter, respectively, and patients III and IV are
siblings. In all patients (seven females and two males, aged 7–51 yr), the
diagnosis was based upon the occurrence of AHO manifestations to-
gether with PTH resistance (i.e. hypocalcemia, hyperphosphatemia, and
raised serum PTH levels) and hypothyroidism because of resistance to
TSH (documented by raised serum TSH levels with an exaggerated
response to TRH, in the absence of antithyroid antibodies and in the
Abbreviations: AHO, Albright’s hereditary osteodystrophy; BMI,
body mass index; IGFBP, IGF-binding protein; PHP, pseudohypopara-
thyroidism; PHP Ia, PHP type Ia.
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presence of a normal thyroid scan). Oligoamenorrhea was present in
three of the four females in the postpubertal age. The required therapy
(calcium, vitamin D, l-thyroxine, and hormone replacement therapy)
was not discontinued during the study. Dysarmonic short stature
(height below the fifth percentile for chronological age in all patients
except for patient VI, whose height was at the 20th percentile; see Table
1 for details) and overweight [body mass index (BMI), ranging from
25.0–29.5 kg/m2, median 27.05  1.8 kg/m2, with the exception of
patient VII, whose BMI was 19.4 kg/m2] were present in all patients as
part of AHO features. No patient had signs or symptoms of adrenal
insufficiency. Clinical and biochemical details are shown in Table 1.
Informed consent was obtained from all subjects involved in the study.
The study was approved by the local Ethical Committee.
Methods
Sequencing analysis
Genomic DNA was extracted with the phenol-chloroform method
from peripheral blood leukocytes (Nucleon-Amersham Life Science,
Aylesbury, UK). The Gs gene (exons 1–13, GenBank accession no.
AH002748) was then amplified by PCR using the specific primers pre-
viously described (23). Amplification of exons 2–12 included each bor-
dering intron region, and for exon 1, because of the abundance of
guanine and cytosine in the bordering regions, a DNA fragment from
20 bp downstream of the initiation codon to the donor site of intron 1
was amplified. Direct sequencing of the amplified fragments was then
performed using the AmpliTaq BigDye Terminator kit and 310 genetic
analyzer (Perkin-Elmer Corp., Applied Biosystems, Foster City, CA).
Testing
All subjects were tested with GHRH (GHRH 1–29; Geref, Serono,
Italy; 1 g/kg body weight iv at time 0) plus arginine (0.5 g/kg body
weight, L-ARG monohydrochloride iv, from time 0 over 30 min). Blood
samples were drawn from an indwelling catheter inserted in an ante-
cubital vein at15 min and times 0, 15, 30, 45, 60, and 90 min. All studies
started between 0800 and 0900 h after overnight fasting according to the
accepted criteria (24–26): normal GH peak after stimulation (16.5 g/
liter); partial GH deficiency (9–16.5 g/liter); complete GH deficiency
(9 g/liter). On another day, patients were subjected to a low-dose
ACTH test (Synacthen, Novartis, Origgio, Italy; 1 g iv at time 0) with
cortisol evaluation at times 30, 0, 30, 40, and 60 min. Normal values
of cortisol peak after ACTH injection were more than 500 nmol/liter. In
three patients CRH (ovine-CRF, Calbiochem, 1 g/kg body weight iv at
time 0) was injected, and ACTH and cortisol levels were determined at
times 30, 0, 20, 30, 60, 90, and 120 min.
Assays
Serum GH levels were measured by an immunofluorimetric assay
method supplied by AutoDelfia (Wallac OY, Turku, Finland). The sen-
sitivity is 0.01 g/liter, the intra- and interassay coefficients of variation
are 2% and 1.7%, respectively. Serum IGF-I was measured by a RIA
(commercial kit supplied by Mediagnost, Tubingen, Germany) able to
measure total IGF-I by separating IGF-I from IGF-binding protein
(IGFBP) by acidification in IGF-II excess. IGF-II cross-reactivity was less
than 0.05%; the intra- and interassay coefficients of variation was 3.2%
and 7.4%, respectively. Plasma ACTH and serum cortisol levels were
measured by immunoluminometric assay and luminescence immuno-
assay methods, respectively (Nichols Institute, San Juan Capistrano,
CA). The sensitivity was 0.22 pmol/liter and 22 nmol/liter, respectively,
and the inter- and intraassay coefficients of variation were less than 10%
and less than 4.8%, respectively, for both methods. Serum IGFBP3 levels
were measured by RIA (Diagnostic Systems Laboratories, Inc., Webster,
TX). The sensitivity was 0.004 nmol/liter, and the intra- and interassay
coefficients of variation were 3.25 and 5.6%, respectively.
Results
Mutational analysis
Direct sequencing of the amplified genomic DNA frag-
ments revealed heterozygous frameshift mutations in seven T
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of nine patients. In particular, mutations were found in six
affected members of the four families previously described
(23): a 4-bp deletion in exon 7, a 1-bp deletion in exon 5, a 1-bp
deletion in exon 1, and a 2-bp deletion in exon 11, all causing
a premature stop codon in the mutant allele, thus giving rise
to a truncated nonfunctional protein. Moreover, a novel 4-bp
deletion in intron 3 involving and eliminating the donor
splicing site was detected in patient VII. No mutations in the
protein-coding region of the gene were found in patients VIII
and IX.
Endocrine testing
The mean GH response after GHRH plus arginine was
significantly lower in the patient population (9.5  7.1 g/
liter; range 2.6–25), compared with the response in the nor-
mal population (16.5 g/liter) (Fig. 1). In particular, six
patients showed an absent/blunted GH response (peak  9
g/liter, normal values  16.5 g/liter) that is considered
indicative of complete GH deficiency, and two patients (IV
and VI) showed a peak of 13.9 and 13.6g/liter, respectively,
indicative of partial deficiency (24–26). Patient V had a nor-
mal GH response (GH peak 25 g/liter) (Table 1). The pres-
ence of a complete or partial GH deficiency in these patients
was confirmed by the determination of IGF-I levels that were
below the normal limits according to age and sex in seven
patients and in the low-normal range (22.2 nmol/liter; nor-
mal values 15–44) in patients IV and V (Table 1). Determi-
nation of IGFBP3 showed low-normal levels in all of them,
ruling out any elevation that might account for the reduced
IGF-I levels. It is worth noting that patients IV and V were
siblings, probably indicating the presence in this family of a
genetic background somehow protective with respect to GH
secretion.
Basal serum ACTH and cortisol levels were within the
normal range. Cortisol response elicited by 1 g ACTH in-
jection was normal in all patients (Table 1) (normal re-
sponse  500 nmol/liter). Similarly, in the three patients
tested (I, II, IV), CRH injection caused a normal increase in
both plasma ACTH (% 85, 330, 870, respectively, normal
value 50) and cortisol (% 25, 40, 212, respectively, normal
value  20).
Discussion
The present study provides evidence for the presence of
GH deficiency, probably because of resistance to the action
of GHRH, in patients with PHP Ia. The study was performed
on a series of patients with PHP Ia who displayed the typical
AHO features together with PTH and TSH resistance. By
analyzing the entire Gs gene-coding sequence, heterozy-
gous mutations were detected in seven of nine patients
(77%), consistently with previous mutational analysis (27).
To evaluate the presence of resistance to GHRH, these pa-
tients were submitted to a combined provocative test, that
explores the maximal secretory response to GHRH occurring
in association with the inhibition of somatostatin release by
arginine infusion (24, 25). This test, which is one of the most
reliable tests to distinguish normal subjects from GH-
deficient patients during the whole lifespan (24–26), showed
impaired responsiveness to GHRH in almost all patients.
Although it is well known that obesity (BMI  30 kg/m2) is
associated with low spontaneous and stimulated GH secre-
tion (28, 29), it is very unlikely that the severely reduced GH
secretion observed in PHP Ia patients may be due to their
increased body mass because they were only overweight
(BMI between 25 and 29.9 kg/m2), as typically occurs in AHO
syndrome. Moreover, the presence of GH deficiency was
confirmed by the low IGF-I levels found in these patients.
Consistent with a normal pituitary-adrenal function, all
patients had normal cortisol response to 1 g ACTH test, a
low dose that appears to detect mild forms of secondary
hypoadrenalism (30, 31). Moreover, the marked ACTH and
cortisol response to CRH test seems to rule the occurrence of
resistance to CRH in PHP Ia patients, although criteria for
normal ACTH responses to the peptide are lacking.
Our data on GH deficiency in patients with PHP Ia are in
agreement with some anecdotal case reports (32–34) and in
contrast with those by Faull et al. (35), who described a large
family with five affected members who all displayed normal
GH responses to a variety of stimuli. It is possible that a
specific mutation able to prevent Gs binding to some re-
ceptors but not to others, as it has already been demonstrated
in one family (36), could explain why in this particular family
Gs binding to the GHRH receptor appears to be normal,
despite a defective coupling to PTH and TSH receptors.
Alternatively, in this family a protective genetic background
may be hypothesized, in analogy with the two siblings here
reported.
The demonstration of GH deficiency in patients with PHP
Ia provides new support to the view that tissue-specific im-
printing of Gsmay be the potential mechanism responsible
for end-organ resistance to the action of different hormones
that characterizes this disease. Indeed, recent reports dem-
onstrated that in the thyroid and gonad, Gs transcription
mainly derived from the maternal allele (21, 22), thus ex-
plaining why only patients with maternally inherited mu-
tations are resistant to TSH and gonadotropins. The obser-
vation of an almost exclusive maternal origin of Gs
transcription in the human normal pituitary (20, 21) triggered
FIG. 1. GH response to GHRH plus arginine injection in the nine
PHP Ia patients. The shaded area indicates partial GH deficiency (GH
peak between 9 and 16.5 g/liter). As described in Results, except for
one patient, who showed a normal GH response to stimuli, all the
other patients displayed an impaired GH response.
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the question why this gland was not classically included
among the target organs resistant to hormone action in PHP
Ia patients. Indeed, because it is well established that both
GHRH and CRH mediate their action on hormone secretion
and cell differentiation by activating specific receptors that
are coupled with Gs, the maternal origin of Gs transcrip-
tion in the pituitary would be expected to result in impaired
function of somatotroph and/or corticotroph in PHP Ia pa-
tients. Our data demonstrating a defective GH secretion and
normal hypothalamic-pituitary-adrenal axis are only appar-
ently in contrast with this finding of Gs imprinting in the
pituitary taken as a whole. In fact, the predominance of the
maternally derived transcript observed in pituitary tissues
occurred at a variable extent (21), probably because of the
cellular heterogeneity of this gland. Taking into account that
somatotroph cells account for about 50% of the adenohy-
pophysial population and corticotrophs represent no more
than 10–15% (37), it is tempting to speculate that Gs im-
printing was indeed present in the somatotroph population,
but not in the corticotroph cells, in which the maternal and
paternal allele would be equally represented but contributed
to a lesser extent to the overall expression of the gene in the
total gland. This interpretation is also consistent with the lack
of reports of overt or subclinical hypoadrenalism in PHP Ia
patients.
To date, the relevancy of GH deficiency on final height in
patients with PHP Ia is unknown. However, taking into
consideration that patients with pseudo-pseudohypopara-
thyroidism, although not displaying any endocrine abnor-
mality, are characterized by short stature as their relatives
with PHP, a crucial role of GH deficiency in the determina-
tion of short stature in these patients seems unlikely. How-
ever, although we may hypothesize only a minor effect on
growth, PHP Ia patients might benefit from GH replacement
therapy for amelioration of other parameters, such as body
composition, lipid profile, bone mineral density, physical
performance, and quality of life (26).
A last consideration can be made on the age of onset of
pituitary resistance. All the patients considered in this study
have been investigated for GH and ACTH deficiency at least
5 yr after the diagnosis of PHP Ia, and it is possible that
subclinical GH deficiency might have developed over the
years in these patients. Consistent with this view, it has been
demonstrated that imprinting can be a process beginning
and evolving in postnatal life (38–40), and the observation
that PHP Ia patients do not show any sign of hormone re-
sistance at birth but generally develop hypocalcemia, hypo-
thyroidism, and hypogonadism over childhood or adoles-
cence supports this hypothesis.
In conclusion, we report nine patients with PHP Ia dis-
playing, in addition to PTH and TSH resistance, also resis-
tance to the action of GHRH. These data are consistent with
the recent demonstration of Gs gene imprinting in the hu-
man pituitary gland and suggest that patients with known
mutations in this gene should be carefully monitored for GH
deficiency. Further studies will be necessary to determine the
possible beneficial effects of GH replacement in these
patients.
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